,for, Item ID-
  • #1240499
  • Takeda Pharmaceuticals America Inc #64764010821

ENTYVIO® Vedolizumab 108 mg / 0.68 mL Injection

ENTYVIO, PEN 108MG/0.68ML

Features

  • ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease
  • More …
Container Type
Prefilled Injection Pen Single-Dose Vial
Strength
108 mg / 0.68 mL 300 mg
Type
Intravenous Subcutaneous
  Log In to Order
or

Product Specifications


Features
  • ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease

Frequently Viewed Together